Human H6PD activation kit by CRISPRa

CAT#: GA106402

H6PD CRISPRa kit - CRISPR gene activation of human hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
Anti-H6PD mouse monoclonal antibody, clone OTI2A7 (formerly 2A7)
    • 100 ul

CNY 1,999.00
CNY 2,700.00


H6PD (Myc-DDK-tagged)-Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) (H6PD)
    • 10 ug

CNY 8,688.00


Anti-H6PD mouse monoclonal antibody, clone OTI2A7 (formerly 2A7)
    • 30 ul

CNY 800.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol H6PD
Locus ID 9563
Kit Components

GA106402G1, H6PD gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA106402G2, H6PD gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA106402G3, H6PD gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001282587, NM_004285
Synonyms CORTRD1; G6PDH; GDH
Summary There are 2 forms of glucose-6-phosphate dehydrogenase. G form is X-linked and H form, encoded by this gene, is autosomally linked. This H form shows activity with other hexose-6-phosphates, especially galactose-6-phosphate, whereas the G form is specific for glucose-6-phosphate. Both forms are present in most tissues, but H form is not found in red cells. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...